$AGIO News

Why Is Agios Pharma Stock Soaring Tuesday?

RBC Capital Maintains Sector Perform on Agios Pharmaceuticals, Raises Price Target to $32

Truist Securities Maintains Buy on Agios Pharmaceuticals, Raises Price Target to $41

Agios Pharma Says FDA Accepts sNDA For Mitapivat In Sickle Cell Disease With Priority Review; PDUFA Goal Date November 1

B of A Securities Maintains Buy on Agios Pharmaceuticals, Raises Price Target to $46

Agios to Host Second Quarter 2026 Financial Results Conference Call and Webcast on July 30 at 8:00 a.m. ET

AGIO Stock Surges 35% in Six Months: What's Driving It?

Agios Pharmaceuticals, Inc. (AGIO) Discusses New Data and Strategic Expansion in Rare Hematology at EHA Investor Event - Slideshow

Reported Saturday, Agios Presents RISE UP Phase 3 Data At EHA 2026 Showing Mitapivat Achieves 40.6% Hemoglobin Response Rate And 41.1% Reduction In Transfusion Burden Versus Placebo In Sickle Cell Disease

Agios Pharmaceuticals Touts Mitapivat Gains Despite Sickle Cell Pain Miss

Agios Pharmaceuticals, Inc. (AGIO) Discusses New Data and Strategic Expansion in Rare Hematology at EHA Investor Event Transcript

Agios Showcases RISE UP Phase 3 Results at EHA 2026 Plenary Session Reinforcing Strong Anti-Hemolytic Profile of Mitapivat in Sickle Cell Disease

JP Morgan Maintains Neutral on Agios Pharmaceuticals, Lowers Price Target to $31

AGIO Secures Global Rights to Late-Stage Rare Blood Disorder Candidate

Agios Pharmaceuticals licenses global rights to Oscotec's SYK inhibitor cevidoplenib

Agios Pharmaceuticals, Inc. (AGIO) Discusses Global License Agreement for Cevidoplenib and Strategic Expansion in Rare Hematology Transcript

AGIO Halts Tebapivat Development in Myelodysplastic Syndromes

Agios Pharmaceuticals, Inc. (AGIO) Discusses Global License Agreement for Cevidoplenib and Strategic Expansion in Rare Hematology - Slideshow

Agios Enters Exclusive Global License Agreement with Oscotec to Develop and Commercialize Next-Generation SYK Inhibitor Cevidoplenib

Agios Acquires Global Rights to Experimental Blood Disorder Drug From South Korea's Oscotec